Print

Novo Nordisk A/S (NVO) Faces New Hurdle for Degludec  
7/18/2012 7:00:44 AM

BAGSVAERD, DENMARK--(Marketwire - July 18, 2012) -

Company Announcement No 46 / 2012: http://hugin.info/2013/R/1627515/520914.pdf


This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and other applicable laws; and

(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Novo Nordisk A/S via Thomson Reuters ONE

[HUG#1627515]


Further information:

Media:
Mike Rulis
Tel: (+45) 3079 3573
Email Contact

Investors:
Kasper Roseeuw Poulsen
Tel: (+45) 4442 4303
Email Contact

Frank Daniel Mersebach
Tel: (+45) 4442 0604
Email Contact

Lars Borup Jacobsen
Tel: (+45) 3075 3479
Email Contact

In North America:
Ken Inchausti
Tel: (+1) 609 514 8316
Email Contact

Jannick Lindegaard
Tel: (+1) 609 786 4575
Email Contact


//-->